508 related articles for article (PubMed ID: 26273063)
21. Generation of dendritic cells using cell culture bags--description of a method and review of literature.
Büchler T; Kovárová L; Musilová R; Bourková L; Ocadlíková D; Buliková A; Hanák L; Michálek J; Hájek R
Hematology; 2004 Jun; 9(3):199-205. PubMed ID: 15204101
[TBL] [Abstract][Full Text] [Related]
22. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
[TBL] [Abstract][Full Text] [Related]
24. Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer.
Rojas-Sepúlveda D; Tittarelli A; Gleisner MA; Ávalos I; Pereda C; Gallegos I; González FE; López MN; Butte JM; Roa JC; Fluxá P; Salazar-Onfray F
Cancer Immunol Immunother; 2018 Dec; 67(12):1897-1910. PubMed ID: 29600445
[TBL] [Abstract][Full Text] [Related]
25. Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
Schaller TH; Sampson JH
Expert Rev Vaccines; 2017 Jan; 16(1):27-36. PubMed ID: 27500911
[TBL] [Abstract][Full Text] [Related]
26. Experimental production of clinical-grade dendritic cell vaccine for acute myeloid leukemia.
Tan YF; Sim GC; Habsah A; Leong CF; Cheong SK
Malays J Pathol; 2008 Dec; 30(2):73-9. PubMed ID: 19291915
[TBL] [Abstract][Full Text] [Related]
27. Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors.
Gulen D; Abe F; Maas S; Reed E; Cowan K; Pirruccello S; Wisecarver J; Warkentin P; Northam M; Turken O; Coskun U; Senesac J; Talmadge JE
Int Immunopharmacol; 2008 Dec; 8(13-14):1728-36. PubMed ID: 18793758
[TBL] [Abstract][Full Text] [Related]
28. Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.
Chiang CL; Maier DA; Kandalaft LE; Brennan AL; Lanitis E; Ye Q; Levine BL; Czerniecki BJ; Powell DJ; Coukos G
J Transl Med; 2011 Nov; 9():198. PubMed ID: 22082029
[TBL] [Abstract][Full Text] [Related]
29. The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
Reardon DA; Mitchell DA
Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787
[TBL] [Abstract][Full Text] [Related]
30. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma.
Jie X; Hua L; Jiang W; Feng F; Feng G; Hua Z
Cell Biochem Biophys; 2012 Jan; 62(1):91-9. PubMed ID: 21909820
[TBL] [Abstract][Full Text] [Related]
31. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.
Dobrovolskienė N; Pašukonienė V; Darinskas A; Kraśko JA; Žilionytė K; Mlynska A; Gudlevičienė Ž; Mišeikytė-Kaubrienė E; Schijns V; Lubitz W; Kudela P; Strioga M
Vaccine; 2018 Jul; 36(29):4171-4180. PubMed ID: 29895501
[TBL] [Abstract][Full Text] [Related]
32. Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon γ production.
Erhart F; Weiss T; Klingenbrunner S; Fischhuber K; Reitermaier R; Halfmann A; Blauensteiner B; Lötsch D; Spiegl-Kreinecker S; Berger W; Sialana FJ; Lubec G; Felzmann T; Dohnal A; Visus C
Cytotherapy; 2019 Jun; 21(6):643-658. PubMed ID: 30975602
[TBL] [Abstract][Full Text] [Related]
33. Active dendritic cell immunotherapy for glioblastoma: Current status and challenges.
Polyzoidis S; Tuazon J; Brazil L; Beaney R; Al-Sarraj ST; Doey L; Logan J; Hurwitz V; Jarosz J; Bhangoo R; Gullan R; Mijovic A; Richardson M; Farzaneh F; Ashkan K
Br J Neurosurg; 2015 Apr; 29(2):197-205. PubMed ID: 25541743
[TBL] [Abstract][Full Text] [Related]
34. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cell-based immunotherapy for the treatment of hematological malignancies.
Büchler T; Michalek J; Kovarova L; Musilova R; Hajek R
Hematology; 2003 Apr; 8(2):97-104. PubMed ID: 12745659
[TBL] [Abstract][Full Text] [Related]
37. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cell vaccines to combat glioblastoma.
Wheeler CJ
Expert Rev Neurother; 2010 Apr; 10(4):483-6. PubMed ID: 20367199
[No Abstract] [Full Text] [Related]
40. Automated Good Manufacturing Practice-compliant generation of human monocyte-derived dendritic cells from a complete apheresis product using a hollow-fiber bioreactor system overcomes a major hurdle in the manufacture of dendritic cells for cancer vaccines.
Uslu U; Erdmann M; Wiesinger M; Schuler G; Schuler-Thurner B
Cytotherapy; 2019 Nov; 21(11):1166-1178. PubMed ID: 31668486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
